AWD-12-281 (inhaled) (elbion/GlaxoSmithKline)

Curr Opin Investig Drugs. 2005 Nov;6(11):1149-58.

Abstract

elbion (formerly ASTA Medica) and GlaxoSmithKline are developing an inhaled formulation of AWD-12-281 for the potential treatment of chronic obstructive pulmonary disease (COPD). By May 2005, phase II trials of this 5-hydroxyindole PDE4 inhibitor for COPD were ongoing.

Publication types

  • Review

MeSH terms

  • 3',5'-Cyclic-AMP Phosphodiesterases / antagonists & inhibitors*
  • Administration, Inhalation
  • Administration, Topical
  • Amides / administration & dosage
  • Amides / pharmacokinetics
  • Amides / therapeutic use*
  • Aminopyridines / chemistry
  • Animals
  • Benzamides / chemistry
  • Clinical Trials as Topic
  • Cyclic Nucleotide Phosphodiesterases, Type 4
  • Cyclopropanes / chemistry
  • Dermatitis, Atopic / drug therapy*
  • Disease Models, Animal
  • Drug Evaluation, Preclinical
  • Humans
  • Indoles / administration & dosage
  • Indoles / pharmacokinetics
  • Indoles / therapeutic use*
  • Inflammation / chemically induced
  • Inflammation / drug therapy
  • Lipopolysaccharides
  • Ovalbumin
  • Phosphodiesterase Inhibitors / administration & dosage
  • Phosphodiesterase Inhibitors / pharmacokinetics
  • Phosphodiesterase Inhibitors / therapeutic use*
  • Psoriasis / drug therapy*
  • Pulmonary Disease, Chronic Obstructive / drug therapy*
  • Respiratory Tract Diseases / chemically induced
  • Respiratory Tract Diseases / drug therapy
  • Structure-Activity Relationship

Substances

  • AWD 12-281
  • Amides
  • Aminopyridines
  • Benzamides
  • Cyclopropanes
  • Indoles
  • Lipopolysaccharides
  • Phosphodiesterase Inhibitors
  • Roflumilast
  • Ovalbumin
  • 3',5'-Cyclic-AMP Phosphodiesterases
  • Cyclic Nucleotide Phosphodiesterases, Type 4